Zota Health Care

Why is Zota Health Care Ltd falling/rising?

As of 05-Aug, Zota Health Care Ltd's stock price is at 1,251.60, down 0.07%. The stock has declined 13.38% over the past month and 18.97% year-to-date, with weak long-term fundamentals and low investor confidence reflected in minimal mutual fund ownership.

As of 05-Aug, Zota Health Care Ltd's stock price is falling, currently at 1,251.60, reflecting a change of -0.9 (-0.07%). The stock has shown a significant decline over the past month, with a decrease of 13.38%, while the benchmark Sensex has increased by 1.46% during the same period. Year-to-date, the stock has dropped by 18.97%, contrasting with the Sensex's decline of only 5.76%. <BR><BR>Despite some positive indicators, such as a low debt-equity ratio of 0.39 times and a notable growth in net sales of 67.76% for the last quarter, the overall long-term fundamentals appear weak. The company has experienced a staggering -287.32% compound annual growth rate (CAGR) in operating profits over the past five years, coupled with a high debt to EBITDA ratio of 14.58 times, indicating a low ability to service its debt. Furthermore, the stock has recorded a negative EBIT of Rs. -63.91 cr, and profits have fallen by 20.5% over the past year, despite a modest return of 3.73%.<BR><BR>Investor sentiment seems cautious, as evidenced by the low domestic mutual fund ownership of only 0.72%, suggesting a lack of confidence in the company's valuation or business prospects. Additionally, the stock is trading below its moving averages across multiple time frames, indicating a bearish trend. Overall, these factors contribute to the stock's current decline.

Which are the latest news on Zota Health Care?

Should I buy, sell or hold Zota Health Care Ltd?

What does Zota Health Care do?

Zota Health Care Ltd is a pharmaceutical company that manufactures and markets pharmaceutical, ayurvedic, nutraceutical, and OTC products. As of March 2026, it reported net sales of 163 Cr and a net loss of 14 Cr, with a market cap of INR 4,201 Cr.

Overview: <BR>Zota Health Care Ltd is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Small Cap.<BR><BR>History: <BR>Zota Health Care Ltd was incorporated on July 12, 2000. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 163 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -14 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 4,201 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.07% <BR>Debt Equity: 0.25 <BR>Return on Equity: -9.80% <BR>Price to Book: 6.05<BR><BR>Contact Details: <BR>Address: Zota House 2/896 Hira Modi St, Sagrampura Surat Gujarat : 395002 <BR>Tel: 91-261-2331601 <BR>Email: info@zotahealthcare.com <BR>Website: http://www.zotahealthcare.com

How big is Zota Health Care?

As of 10th June, Zota Health Care Ltd has a market capitalization of 4,201.00 Cr and reported Net Sales of 538.66 Cr with a Net Profit loss of 73.94 Cr over the latest four quarters.

As of 10th June, Zota Health Care Ltd has a market capitalization of 4,201.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Zota Health Care reported Net Sales of 538.66 Cr. However, the company experienced a loss of 73.94 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 223.68 Cr and Total Assets were valued at 430.49 Cr.

Who are in the management team of Zota Health Care?

The management team of Zota Health Care includes Chairman Ketankumar Zota, Managing Director Moxesh Zota, and several Whole-time Directors, along with independent directors and a company secretary, all of whom guide the company's operations and strategy.

The management team of Zota Health Care includes the following individuals:<BR><BR>1. **Ketankumar Zota** - Chairman & Non-Executive Director<BR>2. **Moxesh Zota** - Managing Director<BR>3. **Kamlesh Zota** - Whole-time Director<BR>4. **Himanshu Zota** - Whole-time Director<BR>5. **Manukant Zota** - Whole-time Director<BR>6. **Varsaben Mehta** - Independent Director<BR>7. **Ashvin Variya** - Company Secretary<BR>8. **Bhumi Maulik Doshi** - Additional Independent Director<BR>9. **Dhiren Prafulbhai Shah** - Independent Director<BR>10. **Jayshreeben N Mehta** - Independent Director<BR><BR>This team plays a crucial role in guiding the company's operations and strategy.

Who are the peers of the Zota Health Care?

Zota Health Care's peers include Innova Captab, Senores Pharma, Bliss GVS Pharma, Orchid Pharma, Guj. Themis Bio, Advanced Enzyme, IOL Chemicals, Gufic BioScience, SMS Pharma, and Panacea Biotec. Zota Health Care has average management risk and a 1-year return of 26.97%, lower than Senores Pharma's 114.68% but higher than Gufic BioScience's -2.31%.

Peers: The peers of Zota Health Care are Innova Captab, Senores Pharma., Bliss GVS Pharma, Orchid Pharma, Guj. Themis Bio., Advanced Enzyme, IOL Chemicals, Gufic BioScience, SMS Pharma, and Panacea Biotec.<BR><BR>Quality Snapshot: Excellent management risk is observed at Innova Captab and Guj. Themis Bio., while Average management risk is found at Senores Pharma., Bliss GVS Pharma, Advanced Enzyme, IOL Chemicals, Gufic BioScience, SMS Pharma, and Zota Health Care. Below Average management risk is noted at Orchid Pharma and Panacea Biotec. Growth is Excellent at Senores Pharma., while Below Average growth is seen at Innova Captab, Bliss GVS Pharma, Orchid Pharma, Zota Health Care, Guj. Themis Bio., Advanced Enzyme, IOL Chemicals, Gufic BioScience, SMS Pharma, and Panacea Biotec. Capital Structure is Excellent at Innova Captab, Bliss GVS Pharma, Guj. Themis Bio., Advanced Enzyme, and IOL Chemicals, while Good is found at Senores Pharma., Average at Gufic BioScience and SMS Pharma, and Below Average at Orchid Pharma, Zota Health Care, and Panacea Biotec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Senores Pharma. at 114.68%, while the lowest is Gufic BioScience at -2.31%. Zota Health Care's 1-year return is 26.97%, which is significantly lower than Senores Pharma.'s but higher than Gufic BioScience's. Additionally, the peers with negative six-month returns include Orchid Pharma and Guj. Themis Bio.

Are Zota Health Care Ltd latest results good or bad?

Zota Health Care Ltd's latest results show strong revenue growth of 67.76% year-on-year, reaching ₹163.18 crores, but the company reported a net loss of ₹56 crores for FY25 and ₹14.17 crores in Q4 FY26, raising concerns about its profitability despite improved operating margins. Investors should be cautious due to ongoing losses and operational challenges.

Zota Health Care Ltd's latest results present a mixed picture. On one hand, the company achieved impressive top-line growth of 67.76% year-on-year, with revenues reaching ₹163.18 crores in Q4 FY26. This marks the seventh consecutive quarter of revenue growth, indicating strong demand in both domestic and export markets.<BR><BR>However, the profitability situation is concerning. For the full fiscal year FY25, Zota Health Care reported a net loss of ₹56 crores, and in Q4 FY26, the net loss was ₹14.17 crores, which is a significant deterioration from the previous quarter's loss. The company's operating margin improved to 5.34%, the highest in seven quarters, but this improvement has not translated into profitability due to high employee costs, depreciation charges, and interest expenses.<BR><BR>Overall, while Zota Health Care is expanding its revenues, the persistent losses and challenges in operational efficiency raise serious questions about the sustainability of this growth. Investors may want to approach the company with caution, given the ongoing profitability issues despite strong revenue growth.

Is Zota Health Care technically bullish or bearish?

As of December 1, 2025, Zota Health Care's trend is mildly bullish due to daily moving averages, despite mixed signals from weekly and monthly indicators suggesting some caution.

As of 1 December 2025, the technical trend for Zota Health Care has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating bullish momentum. However, the weekly MACD and KST are both mildly bearish, suggesting some caution. The monthly MACD remains bullish, which supports the overall positive outlook. The RSI shows a bearish signal on the monthly timeframe, indicating potential weakness. Overall, while there are mixed signals across different timeframes, the daily indicators provide a bullish bias.

How has been the historical performance of Zota Health Care?

Zota Health Care has experienced significant revenue growth, increasing from 85.63 Cr in March 2019 to 292.97 Cr in March 2025, but has faced severe profitability declines, reporting a loss of -56.74 Cr in March 2025 compared to a profit of 8.91 Cr in March 2022, alongside deteriorating cash flow and rising debt.

Answer:<BR>The historical performance of Zota Health Care shows significant fluctuations in revenue and profitability over the years, culminating in a challenging fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Zota Health Care's net sales have shown a consistent upward trend, increasing from 85.63 Cr in March 2019 to 292.97 Cr in March 2025. However, the total expenditure has also risen sharply, reaching 298.70 Cr in March 2025, which has led to an operating profit (PBDIT) of -5.73 Cr, a stark decline from the positive figures seen in previous years. The company reported a profit before tax of -57.64 Cr in March 2025, compared to a profit of 12.44 Cr in March 2022, indicating a significant downturn. The profit after tax has similarly worsened, resulting in a loss of -56.74 Cr in March 2025, down from a profit of 8.91 Cr in March 2022. The company's total assets have increased to 430.49 Cr in March 2025, up from 85.48 Cr in March 2021, while total liabilities have also surged to 430.49 Cr, reflecting a growing debt position. Cash flow from operating activities has deteriorated, showing a cash outflow of -49.00 Cr in March 2025, compared to a positive cash flow of 13.00 Cr in March 2022. Overall, while Zota Health Care has expanded its revenue base, it faces significant challenges in profitability and cash flow management.

Who are the top shareholders of the Zota Health Care?

The top shareholders of Zota Health Care include Himansubhai Muktilal Zota, the largest individual shareholder with 10.65%, and Asha Mukul Agrawal, the highest public shareholder at 5.54%. Promoters hold a pledged 0.2573%, while 11 Foreign Institutional Investors own 3.6%, and individual investors collectively hold 24.79%.

The top shareholders of Zota Health Care include the promoters, with Himansubhai Muktilal Zota being the largest individual shareholder, holding 10.65% of the company. Additionally, Asha Mukul Agrawal is the highest public shareholder, owning 5.54%. The company also has 11 Foreign Institutional Investors (FIIs) holding a combined 3.6%. Individual investors collectively hold 24.79% of the shares. Notably, the promoters have a pledged holding of 0.2573%.

Is Zota Health Care overvalued or undervalued?

As of February 14, 2023, Zota Health Care is considered risky and overvalued with poor financial metrics, including a PE ratio of -49.15 and a ROE of -25.21%, despite having outperformed the Sensex with a 1-year return of 93.8%.

As of 14 February 2023, the valuation grade for Zota Health Care has moved from expensive to risky, indicating a significant shift in its perceived value. The company appears to be overvalued, with a PE ratio of -49.15, an EV to EBITDA of -507.40, and a Price to Book Value of 12.39. These ratios suggest that the company's financial performance is not only poor but also unsustainable at its current valuation.<BR><BR>In comparison to its peers, Zota Health Care's valuation metrics are concerning, particularly when looking at the negative PEG ratio of 0.00 and a ROE of -25.21%. While some peers may have better financial health, Zota's metrics highlight its struggles in generating returns. Notably, the stock has outperformed the Sensex over various time frames, including a 1-year return of 93.8% compared to the Sensex's 7.87%, but this performance does not mitigate the underlying valuation concerns.

When is the next results date for Zota Health Care?

No Upcoming Board Meetings

What is the bonus history of the Zota Health Care?

Zota Health Care announced a 4:10 bonus issue on July 25, 2019, with a record date of July 26, 2019, meaning shareholders received 4 additional shares for every 10 shares held.

Zota Health Care has a bonus history that includes a 4:10 bonus issue announced on July 25, 2019. The record date for this bonus was July 26, 2019. This means that for every 10 shares held, shareholders received an additional 4 shares as part of this bonus issue. If you have any more questions about Zota Health Care or need further details, feel free to ask!

Has Zota Health Care declared dividend?

Zota Health Care Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 20, 2024. Despite a low dividend yield of 0.1%, the company has shown strong price returns, achieving a total return of 579.53% over the past five years.

Zota Health Care Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 20 Sep 24<BR><BR>Dividend Yield: 0.1%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Zota Health Care achieved a price return of 56.73% with no dividend return, resulting in a total return of 56.73%.<BR><BR>Over the past year, the company recorded a price return of 103.34% and a dividend return of 0.19%, leading to a total return of 103.53%.<BR><BR>In the two-year period, Zota Health Care experienced a price return of 205.08% and a dividend return of 0.55%, culminating in a total return of 205.63%.<BR><BR>For the three-year period, the price return was 247.63% with a dividend return of 1.44%, resulting in a total return of 249.07%.<BR><BR>Over the last four years, the company saw a price return of 450.58% and a dividend return of 2.30%, achieving a total return of 452.88%.<BR><BR>In the five-year span, Zota Health Care had a price return of 575.72% and a dividend return of 3.81%, leading to a total return of 579.53%.<BR><BR>Overall, Zota Health Care has declared a dividend, and while the dividend yield is relatively low, the company has demonstrated strong price returns across all periods, indicating robust growth and potential for investors.